Enliven Therapeutics Inc’s recent filing unveils that its CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P unloaded Company’s shares for reported $0.27 million on Aug 29 ’24. In the deal valued at $22.49 per share,12,000 shares were sold. As a result of this transaction, Lyssikatos Joseph P now holds 1,077,936 shares worth roughly $25.08 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Hohl Benjamin sold 4,250 shares, generating $95,782 in total proceeds. Upon selling the shares at $22.54, the CHIEF FINANCIAL OFFICER now owns 0 shares.
Before that, Kintz Samuel sold 12,000 shares. Enliven Therapeutics Inc shares valued at $274,718 were divested by the PRESIDENT AND CEO at a price of $22.89 per share. As a result of the transaction, Kintz Samuel now holds 1,049,255 shares, worth roughly $24.42 million.
H.C. Wainwright initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on September 09, 2024; the price target was $37. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Mizuho began covering ELVN with “Buy” recommendation on April 09, 2024. Jefferies started covering the stock on March 29, 2023. It rated ELVN as “a Buy”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock jump 1.17% to $23.27. Over the last five days, the stock has gained 4.82%. Enliven Therapeutics Inc shares have risen nearly 68.14% since the year began. Nevertheless, the stocks have risen 39.93% over the past one year. While a 52-week high of $27.67 was reached on 07/29/24, a 52-week low of $9.80 was recorded on 03/15/24. SMA at 50 days reached $23.14, while 200 days put it at $18.67.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 22.40, which if violated will result in even more drops to 21.53. On the upside, there is a resistance level at 24.16. A further resistance level may holdings at 25.05. The Relative Strength Index (RSI) on the 14-day chart is 54.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 32.04%. Stochastics %K at 47.00% indicates the stock is a holding.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2024-08-15, growing by 74387.0 shares to a total of 5.32 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 5.25 million shares. There was a rise of 1.4%, which implies that there is a positive sentiment for the stock.
